Rapid, accessible, globally distributed RNA vaccine manufacture on demand

人类面临的最大挑战之一是消除传染病的生存威胁，包括人畜共患大流行病，如未来X病的威胁。英国有一个千载难逢的机会，从其COVID 19投资中创造一个长期的遗产，以建立一个世界领先的行业，使人类能够以环境可持续和经济可及的方式减轻甚至消除传染病。疫苗是现代医学的伟大成功故事之一，根除或控制了许多具有重大全球意义的严重感染，并改善了数百万人的生活。然而，尽管在开发新疫苗技术（如合成RNA疫苗）方面取得了重大进展，但COVID 19已经证明了经典疫苗制造方法的许多挑战和效率低下，阻碍了全球数百万人的快速获取。BiologIC Technologies带来了颠覆性的工业4.0技术，使分布式端到端生物制造成为可能。目标是建立一种医疗技术，用于快速、经济上可获得、环境上可持续、全球分布、端到端的RNA疫苗按需制造。该系统将大幅降低疫苗成本，并将灵活的制造分配到快速发展的供应链中的任何需要点。该系统的灵感来自于用于快速规模化生产的计算机架构。系统中的重大创新包括3D打印生物处理器在连续生产中的新应用，集成过程分析技术实现的新生物工艺流程，以显着降低疫苗成本，以及实施分布式生产的颠覆性技术。在过程创新中心的支持下，世卫组织将就mRNA疫苗构建和生物过程提供咨询，该项目的特别好处包括通过向世界各地不同社会经济群体的人们提供负担得起的和公平的疫苗需求，减少传染病造成的死亡和疾病。该项目将在前景广阔的RNA疫苗领域带来直接的商业利益，创造COVID 19疫苗遗产，并使英国成为这一新合成生物学行业的全球领导者。

One of the greatest challenges faced by humanity is to eliminate the existential threat of infectious diseases including zoonotic pandemics such as the threat of a future Disease X. The UK has a once-in-a-generation opportunity to create a long-term legacy from its COVID19 investments to build a world-leading industry that allows humanity to mitigate, or even eliminate, infectious diseases in an environmentally sustainable and economically accessible manner.Vaccines are one of the great success stories of modern medicine, having eradicated or controlled many severe infections of major global importance and improved the lives of millions. However, whilst significant progress has been made in developing new vaccine technologies such as synthetic RNA vaccines, COVID19 has demonstrated the many challenges and inefficiencies of classical vaccine manufacturing approaches, preventing rapid global access by millions of people.BiologIC Technologies brings disruptive industry 4.0 technology that enables distributed end-to-end biomanufacturing. The objective is to build a medical technology for rapid, economically accessible, environmentally sustainable, globally distributed, end-to-end RNA vaccine manufacture on demand.The system will substantially reduce vaccine costs and distribute flexible manufacturing to any point of need in the rapidly evolving supply chain. The system is inspired by computer architectures for rapid scale out production.Substantial innovations within the system include the novel application of 3D-printed bioprocessors in continuous manufacturing, new bioprocess flows enabled by integrated Process Analytical Technology to significantly reduce vaccine cost and implementation of a disruptive technology for distributed manufacture.Supported by Centre for Process Innovation, who will advise on mRNA vaccine constructs and bioprocesses, particular benefits of this project include reducing deaths and illness from infectious diseases by providing affordable and equitable access to vaccines by people of diverse socio-economic groups on demand around the world. The project will deliver direct commercial benefit in the promising field of RNA vaccines, creating a COVID19 vaccine legacy and establishing the UK as a global leader in this new synthetic biology industry.